This Week's Issue Sponsored by:
SEPTEMBER 19, 2018
Deal or No Deal: Brexit and the Implications for Pharma
by Patricia Van Arnum, DCAT Editorial Director
Prime Minister Theresa May faces external and internal hurdles and the possibility of a “no deal,” meaning the UK would leave the European Union (EU) without a Brexit agreement. What is the impact for pharmaceutical companies in terms of regulation and supply?

Pharma Manufacturing: Top 10 Trends and Investments
by Patricia Van Arnum, DCAT Editorial Director

What are the key developments in pharma manufacturing? From large-scale biomanufacturing projects, to advances in cell and gene therapy production, and continuous manufacturing, DCAT Value Chain Insights looks at significant investments and technical gains. 

Don't Miss Top Industry News : The companion newsletter delivered electronically to DCAT members every Friday.
About the Editor
Patricia Van Arnum has more than 20 years of experience as a business and science editor, covering the chemical, pharmaceutical, biopharmaceutical, and fine-chemicals industries. Ms. Van Arnum was Executive Editor of  Pharmaceutical Technology  from 2006 to 2014 and Executive Editor of  ICIS Chemical Business  and  Chemical Market Reporter  ( CMR ) from 1995 to 2005.
DCAT Value Chain Insights is produced and distributed by the Drug, Chemical and Associated Technologies Association .
To learn more, please visit www.dcat.org .